Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study-Reference-Cited by-同舟云学术

Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study

Published:2022-04-10 Issue:11 Volume:21 Page:1411-1422
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Kaku Kohei¹^ORCID,Yamamoto Kazuhiro²^ORCID,Fukushima Yumiko³,Mizuno Seiko⁴,Nitta Daisuke³^ORCID

Affiliation:

1. Department of Medicine, Kawasaki Medical School, Okayama, Japan

2. Department of Cardiovascular Medicine, and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Tottori, Japan

3. Medicine Division, Nippon Boehringer Ingelheim Co. Ltd, Tokyo, Japan

4. Medicines Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan

Funder

the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2022.2062322

Reference34 articles.

1. Review: The epidemiology of lifestyle and risk for type 2 diabetes

2. Elevated Rates of Diabetes in Pacific Islanders and Asian Subgroups

3. Twelve-year trends of increasing overweight and obesity in patients with diabetes: the Shiga Diabetes Clinical Survey

4. Prevalence of Obesity and Its Influence on Achievement of Cardiometabolic Therapeutic Goals in Chinese Type 2 Diabetes Patients: An Analysis of the Nationwide, Cross-Sectional 3B Study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study);Diabetes Therapy;2023-07-06

2. Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub‐analysis of the DIVERSITY‐CVR study;Diabetes, Obesity and Metabolism;2023-05-08